ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The successful application of tyrosine kinase inhibitors (TKIs) targeting the adenosine triphosphate binding site of BCR::ABL1, such as imatinib (IM), has greatly improved the event-free survival of CML patients (Ma et al., 2014; Kalmanti et al., 2015).